Eli Lilly and Company $LLY Shares Bought by Mirabella Financial Services LLP

Mirabella Financial Services LLP grew its holdings in Eli Lilly and Company (NYSE:LLY) by 112.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,365 shares of the company’s stock after acquiring an additional 2,837 shares during the period. Mirabella Financial Services LLP’s holdings in Eli Lilly and Company were worth $4,085,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Eli Lilly and Company by 35.0% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 101,385 shares of the company’s stock worth $77,084,000 after buying an additional 26,259 shares during the last quarter. Moneta Group Investment Advisors LLC increased its holdings in shares of Eli Lilly and Company by 16.3% in the 3rd quarter. Moneta Group Investment Advisors LLC now owns 14,493 shares of the company’s stock valued at $11,058,000 after acquiring an additional 2,033 shares during the last quarter. Knollwood Investment Advisory LLC raised its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Knollwood Investment Advisory LLC now owns 13,717 shares of the company’s stock worth $10,466,000 after acquiring an additional 118 shares in the last quarter. LRT Capital Management LLC purchased a new stake in Eli Lilly and Company during the third quarter worth approximately $657,000. Finally, Laird Norton Wetherby Wealth Management LLC boosted its holdings in Eli Lilly and Company by 1.7% in the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 25,429 shares of the company’s stock valued at $19,403,000 after purchasing an additional 419 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Top analysts reiterated bullish ratings and raised targets for LLY, citing continued GLP‑1 growth and the launch of Employer Connect to broaden access to obesity medicines — supporting upside expectations. Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans
• Positive Sentiment: Positive topline Phase 3 pediatric results for EBGLYSS (lebrikizumab) showed meaningful skin clearance and itch relief in children 6 months–18 years, supporting potential label expansion and strengthening Lilly’s immunology growth story. Lilly’s EBGLYSS is first selective IL-13 inhibitor with positive Phase 3 pediatric outcomes
• Positive Sentiment: Management is expanding manufacturing and market reach (including plans to invest in China) to support rollout of orforglipron and other GLP‑1 products, which investors view as capacity/readiness positives for future revenue. Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports
• Neutral Sentiment: A congressional purchase of LLY was disclosed (standard 45‑day lag); such filings can draw attention but are typically not a fresh driver for price moves once public. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: New rival oral GLP‑1 candidates are posting strong mid‑stage weight‑loss results (Structure Therapeutics and others), raising competitive risk that could pressure Lilly’s market share or pricing over time. Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Investor commentary warns valuation already reflects a lot of GLP‑1 upside, suggesting limited near‑term upside and greater sensitivity to any negative news or weaker growth execution. Is There Too Much Bullishness Priced Into Eli Lilly’s Stock Price?

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Leerink Partners increased their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target for the company. Finally, Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Price Performance

Shares of LLY opened at $987.83 on Tuesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a 50-day simple moving average of $1,036.20 and a 200-day simple moving average of $954.12. The company has a market capitalization of $933.32 billion, a price-to-earnings ratio of 43.04, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the firm posted $5.32 EPS. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.